Samsung Biologics
207940.KS · Bio
World's largest contract biologics manufacturer (CDMO). Produces biosimilars and biologics for global pharma.
Latest news
Samsung Biologics to Attend BIO USA for 14th Consecutive Year
KOSPI Tops 8,000, But 52-Week Lows Outnumber Highs
D-7 to 'BIO USA': Korean Firms Mobilize for Licensing, CDMO Megadeals
1,508 Korean Stocks Hit Record Highs, but 1,763 Mark Lows
US Moves to Ease Clinical Trial Barriers, Opening Door for K-Bio
Samsung Biologics Union Moves to Quit Group-Wide Labor Coalition
Samsung Launches 200 Billion Won Bio Fund to Expand Next-Generation Tech Investment
Samsung Biologics Turnover Falls to Record-Low 1.9% Amid Prolonged Labor Dispute
KOSPI Top 10 Race Tightens as Samsung Affiliates Reshuffle Rankings
Samsung Affiliates Push for Bigger Bonuses After Electronics' 600 Million Won Payout
Court Orders Samsung Biologics Union to Pay 20 Million Won for Halting Core Processes
Will K-Bio Squander Its Golden Hour to Strikes?
"Organoids Replace Mice": MEPSGEN, Kangstem Target $5B Alternative Test Market
Samsung Biologics Joins PEGS Boston to Expand Global Client Outreach
Biotech Stocks Buck Market Slump, LigaChem Surges 10%
Samsung Labor-Management Talks Resume with Four Key Hurdles Ahead
Samsung Biologics Labor Talks Fail, but Dialogue to Continue
Samsung Labor Talks Resume With Post-Mediation Starting November 11
Samsung Biologics Files Criminal Complaints Against Union Members
Samsung Biologics Files Criminal Complaint Against Union Members
Samsung Life Science Fund Invests in U.S. Biotech Cartography Biosciences
Samsung Biologics Files Criminal Complaint Against Union Members Over Strike Disruption
